TY - JOUR
T1 - Angiotensin II receptor blocker, valsartan, increases myocardial blood volume and regresses hypertrophy in hypertensive patients
AU - Komatsu, Hiroshi
AU - Yamada, Satoshi
AU - Iwano, Hiroyuki
AU - Okada, Masako
AU - Onozuka, Hisao
AU - Mikami, Taisei
AU - Yokoyama, Shinobu
AU - Inoue, Mamiko
AU - Kaga, Sanae
AU - Nishida, Mutsumi
AU - Shimizu, Chikara
AU - Matsuno, Kazuhiko
AU - Tsutsui, Hiroyuki
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2009
Y1 - 2009
N2 - Background: Although a reduction in myocardial blood volume (MBV), an in vivo index of the myocardial microvasculature, measured by myocardial contrast echocardiography in patients with hypertension (HT), can be demonstrated, it is still unknown whether a decreased MBV can be improved by antihypertensive treatment. Methods and Results: Eleven HT patients (mean age 58 years, 7 men) with left ventricular hypertrophy (LVH) and 10 age- and sex-matched normal controls were studied. Harmonic power Doppler images were acquired at end-diastole of every 6th beat and MBV was calculated as 10 X/10×100%, where X (dB) is myocardial contrast intensity minus the contrast intensity of the adjacent intracavity blood pool. Baseline blood pressure (BP) and left ventricular mass index (LVMI) in the HT patients were higher and MBV was lower than in the controls (2.52±0.37% vs 3.31±0.61%, P<0.01). MBV did not correlate with mean BP, but was inversely correlated with LVMI (r=-0.61, P<0.01). After treatment with valsartan for 6 months, LVMI significantly decreased and MBV increased (2.72±0.26%, P<0.05 vs baseline) in the patients with HT. There was a significant inverse correlation between the changes in MBV and those of LVMI (r=-0.62, P<0.05), but not between MBV and mean BP. Conclusions: Valsartan, an angiotensin II receptor blocker, corrected the decreased MBV in association with regression of LVH in patients with HT.
AB - Background: Although a reduction in myocardial blood volume (MBV), an in vivo index of the myocardial microvasculature, measured by myocardial contrast echocardiography in patients with hypertension (HT), can be demonstrated, it is still unknown whether a decreased MBV can be improved by antihypertensive treatment. Methods and Results: Eleven HT patients (mean age 58 years, 7 men) with left ventricular hypertrophy (LVH) and 10 age- and sex-matched normal controls were studied. Harmonic power Doppler images were acquired at end-diastole of every 6th beat and MBV was calculated as 10 X/10×100%, where X (dB) is myocardial contrast intensity minus the contrast intensity of the adjacent intracavity blood pool. Baseline blood pressure (BP) and left ventricular mass index (LVMI) in the HT patients were higher and MBV was lower than in the controls (2.52±0.37% vs 3.31±0.61%, P<0.01). MBV did not correlate with mean BP, but was inversely correlated with LVMI (r=-0.61, P<0.01). After treatment with valsartan for 6 months, LVMI significantly decreased and MBV increased (2.72±0.26%, P<0.05 vs baseline) in the patients with HT. There was a significant inverse correlation between the changes in MBV and those of LVMI (r=-0.62, P<0.05), but not between MBV and mean BP. Conclusions: Valsartan, an angiotensin II receptor blocker, corrected the decreased MBV in association with regression of LVH in patients with HT.
UR - http://www.scopus.com/inward/record.url?scp=73249132720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73249132720&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-09-0324
DO - 10.1253/circj.CJ-09-0324
M3 - Article
C2 - 19749478
AN - SCOPUS:73249132720
VL - 73
SP - 2098
EP - 2103
JO - Circulation Journal
JF - Circulation Journal
SN - 1346-9843
IS - 11
ER -